Therapeutic treatment of breast cancer based on c-MAF status
US12233077B2 · kind B2 · utility
0Cited by
23References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 11, 2023 |
| Grant date | Feb 25, 2025 |
| Priority date | — |
| Expiry date | May 8, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/158
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding, treating or preventing bone degradation. In some embodiments, the agent for avoiding, treating or preventing bone degradation is zoledronic acid. In other embodiments, the agent is clodronate or denosumab.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.